Encapsulation of mitoxantrone into pegylated SUVs enhances its antineoplastic efficacy

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 70, Issue 2, 2008, Pages 657-665

  Li, ChunLei ^a   Cui, JingXia ^b   Wang, CaiXia ^a   Li, YinGui ^a   Zhang, HongWu ^a   Wang, JinXu ^a   Li, YanHui ^a   Zhang, Lan ^a   Zhang, Li ^a   Guo, WenMin ^a   Wang, YongLi ^b  

^a Zhongqi Pharmaceutical Technology Shijiazhuang Co Ltd   (China)

^b HEBEI MEDICAL UNIVERSITY   (China)

Author keywords

Antitumor efficacy; Drug release; Liposomes; Mitoxantrone; Toxicity; Vesicle size

Indexed keywords

AMMONIUM SULFATE; CHOLESTEROL; LIPOSOME; MITOXANTRONE; PHOSPHATIDYLCHOLINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; ASCITES TUMOR; CONTROLLED STUDY; DOSE RESPONSE; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG MEGADOSE; DRUG RELEASE; DRUG TOLERABILITY; GROWTH INHIBITION; IN VITRO STUDY; KNOCKOUT MOUSE; LIVER METASTASIS; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MOUSE; NONHUMAN; SINGLE DRUG DOSE; SOYBEAN; SURVIVAL RATE; TUMOR GROWTH;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CHEMISTRY, PHARMACEUTICAL; HUMANS; LIPOSOMES; MALE; MICE; MITOXANTRONE; POLYETHYLENE GLYCOLS; SOLUBILITY; TISSUE DISTRIBUTION;

EID: 52949146333     PISSN: 09396411     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejpb.2008.05.019     Document Type: Article

References (34)

1. Neuhaus O., Kieseier B.C., and Hartung H.P. Mitoxantrone in multiple sclerosis. Adv. Neurol. 98 (2006) 293-302
2. Dunn C.J., and Goa K.L. Mitoxantrone: a review of its pharmacological properties and use in acute nonlymphoblastic leukaemia. Drugs Aging 9 2 (1996) 122-147
3. Wiseman L.R., and Spencer C.M. Mitoxantrone. A review of its pharmacology and clinical efficacy in the management of hormone-resistant advanced prostate cancer. Drugs Aging 10 6 (1997) 473-485
4. Benjamin R.S. Rationale for the use of mitoxantrone in the older patient: cardiac toxicity. Semin. Oncol. 22 1 S11 (1995) 11-13
5. van Dalen E.C., van der Pal H.J., Bakker P.J., Caron H.N., and Kremer L.C. Cumulative incidence and risk factors of mitoxantrone-induced cardiotoxicity in children: a systematic review. Eur. J. Cancer 40 5 (2004) 643-652
6. Murray T.J. The cardiac effects of mitoxantrone: do the benefits in multiple sclerosis outweigh the risks?. Expert Opin. Drug Saf. 5 2 (2006) 265-274
7. Kroger N., Damon L., Zander A.R., Wandt H., Derigs G., Ferrante P., Demirer T., and Rosti G. Secondary acute leukemia following mitoxantrone-based high-dose chemotherapy for primary breast cancer patients. Bone Marrow Transplant. 32 12 (2003) 1153-1157
8. Drummond D.C., Meyer O., Hong K., Kirpotin D.B., and Papahadjopoulos D. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol. Rev. 51 4 (1999) 691-743
9. Ugwu S., Zhang A., Parmar M., Miller B., Sardone T., Peikov V., and Ahmad I. Preparation, characterization, and stability of liposome-based formulations of mitoxantrone. Drug Dev. Ind. Pharm. 31 2 (2005) 223-229
10. Ahmad A., Wang Y.F., and Ahmad I. Separation of liposome-entrapped mitoxantrone from nonliposomal mitoxantrone in plasma: pharmacokinetics in mice. Methods Enzymol. 391 (2005) 176-185
11. Gokhale P.C., Pei J., Zhang C., Ahmad I., Rahman A., and Kasid U. Improved safety, pharmacokinetics and therapeutic efficacy profiles of a novel liposomal formulation of mitoxantrone. Anticancer Res. 21 5 (2001) 3313-3321
12. Reszka R., Beck P., Fichtner I., Hentschel M., Richter J., and Kreuter J. Body distribution of free, liposomal and nanoparticle-associated mitoxantrone in B16-melanoma-bearing mice. J. Pharmacol. Exp. Ther. 280 1 (1997) 232-237
13. Rentsch K.M., Horber D.H., Schwendener R.A., Wunderli-Allenspach H., and Hanseler E. Comparative pharmacokinetic and cytotoxic analysis of three different formulations of mitoxantrone in mice. Br. J. Cancer 75 7 (1997) 986-992
14. Schwendener R.A., Fiebig H.H., Berger M.R., and Berger D.P. Evaluation of incorporation characteristics of mitoxantrone into unilamellar liposomes and analysis of their pharmacokinetic properties, acute toxicity, and antitumor efficacy. Cancer Chemother. Pharmacol. 27 6 (1991) 429-439
15. Pestalozzi B.C., Vass A., Adam H., Horber D.H., Schwendener R.A., and Sauter C. Phase II study of liposome-complexed mitoxantrone in patients with advanced breast cancer. Eur. J. Cancer 31 6 (1995) 1024
16. Pestalozzi B., Schwendener R., and Sauter C. Phase I/II study of liposome-complexed mitoxantrone in patients with advanced breast cancer. Ann. Oncol. 3 6 (1992) 445-449
17. Lim H.J., Parr M.J., Masin D., McIntosh N.L., Madden T.D., Zhang G., Johnstone S., and Bally M.B. Kupffer cells do not play a role in governing the efficacy of liposomal mitoxantrone used to treat a tumor model designed to assess drug delivery to liver. Clin. Cancer Res. 6 11 (2000) 4449-4460
18. Lim H.J., Masin D., McIntosh N.L., Madden T.D., and Bally M.B. Role of drug release and liposome-mediated drug delivery in governing the therapeutic activity of liposomal mitoxantrone used to treat human A431 and LS180 solid tumors. J. Pharmacol. Exp. Ther. 292 1 (2000) 337-345
19. Adlakha-Hutcheon G., Bally M.B., Shew C.R., and Madden T.D. Controlled destabilization of a liposomal drug delivery system enhances mitoxantrone antitumor activity. Nat. Biotechnol. 17 8 (1999) 775-779
20. Lim H.J., Masin D., Madden T.D., and Bally M.B. Influence of drug release characteristics on the therapeutic activity of liposomal mitoxantrone. J. Pharmacol. Exp. Ther. 281 1 (1997) 566-753
21. Chang C.W., Barber L., Ouyang C., Masin D., Bally M.B., and Madden T.D. Plasma clearance, biodistribution and therapeutic properties of mitoxantrone encapsulated in conventional and sterically stabilized liposomes after intravenous administration in BDF1 mice. Br. J. Cancer 75 2 (1997) 169-177
22. Cui J.X., Li C.L., Guo W.M., Li Y.H., Wang C.X., Zhang L., Zhang L., Hao Y.L., and Wang Y.L. Direct comparison of two pegylated liposomal doxorubicin formulations: is AUC predictive for toxicity and efficacy?. J. Control. Release 118 2 (2007) 204-215
23. Woodle M.C., and Lasic D.D. Sterically stabilized liposomes. Biochim. Biophys. Acta 1113 2 (1992) 171-199
24. Gabizon A., Shmeeda H., and Barenholz Y. Pharmacokinetics of pegylated liposomal doxorubicin: review of animal and human studies. Clin. Pharmacokinet. 42 5 (2003) 419-436
25. Madden T.D., Harrigan P.R., Tai L.C., Bally M.B., Mayer L.D., Redelmeier T.E., Loughrey H.C., Tilcock C.P., Reinish L.W., and Cullis P.R. The accumulation of drugs within large unilamellar vesicles exhibiting a proton gradient: a survey. Chem. Phys. Lipids 53 1 (1990) 37-46
26. Haran G., Cohen R., Bar L.K., and Barenholz Y. Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. Biochim. Biophys. Acta 1151 2 (1993) 201-215
27. Drummond D.C., Hayes M.E., Noble C.O., Park J.W., Kirpotin D.B., and Guo Z. Intraliposomal trapping agents for improving in vivo liposomal drug formulation stability. In: Gregoriadis G. (Ed). Liposome Technology (2007), Informa Healthcare USA, Inc., New York 149-168
28. Lasic D.D., Frederik P.M., Stuart M.C., Barenholz Y., and McIntosh T.J. Gelation of liposome interior. A novel method for drug encapsulation. FEBS Lett. 312 2-3 (1992) 255-258
29. Li X., Hirsh D.J., Cabral-Lilly D., Zirkel A., Gruner S.M., Janoff A.S., and Perkins W.R. Doxorubicin physical state in solution and inside liposomes loaded via a pH gradient. Biochim. Biophys. Acta 1415 1 (1998) 23-40
30. Lasic D.D., Ceh B., Stuart M.C., Guo L., Frederik P.M., and Barenholz Y. Transmembrane gradient driven phase transitions within vesicles: lessons for drug delivery. Biochim. Biophys. Acta 1239 2 (1995) 145-156
31. Barenholz Y. Amphipathic weak base loading into preformed liposomes having a transmembrane ammonium ion gradient: from the bench to approved doxil. In: Gregoriadis G. (Ed). Liposome Technology (2007), Informa Healthcare USA, Inc., New York 1-26
32. Abraham S.A., Waterhouse D.N., Mayer L.D., Cullis P.R., Madden T.D., and Bally M.B. The liposomal formulation of doxorubicin. In: Duzgunes N. (Ed). Liposomes (2005), Elsevier Inc. 71-97
33. Iden D.L., and Allen T.M. In vitro and in vivo comparison of immunoliposomes made by conventional coupling techniques with those made by a new post-insertion approach. Biochim. Biophys. Acta 1513 2 (2001) 207-216
34. Gabizon A.A. Liposome circulation time and tumor targeting: implications for cancer chemotherapy. Adv. Drug Deliv. Rev. 16 2-3 (1995) 285-294